10 completed, 2 unknown, 1 not yet recruiting, 1 terminated. 4 Not applicable, 4 Phase 3, 4 Phase 4, 1 Early Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Not applicable | 4 | Completed 2, Not yet recruiting 1, Unknown 1 |
| Phase 3 | 4 | Completed 3, Terminated 1 |
| Phase 4 | 4 | Completed 4 |
| Early Phase 1 | 1 | Completed 1 |
Follow Insulin, Short-Acting: new trials by email Literature Review of Insulin, Short-Acting trials Research Report on Insulin, Short-Acting
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Glycemic Targets During CPB in Elderly Diabetes Tight Glycemic Management Protocol, Liberal Glycemic Management Protocol, Short-acting Insulin - Glycemic Management During CPB in Elderly Diabetic Cardiac Surgery | Not applicable | Not yet recruiting | Beijing Anzhen Hospital | 3000 | 2026-04-01 | 2026-03-20 |
| Topical Insulin in Neurotrophic Keratopathy After Diabetic Vitrectomy rapid acting insulin - Corneal Ulcer, Neurotrophic Corneal Ulcer | Unknown | Benha University | 30 | 2023-07-15 | 2023-07-11 | |
| INHALE-3: Afrezza® Combined With Insulin Degludec Versus Usual Care in Adults With Type 1 Diabetes Afrezza, insulin degludec, Rapid-acting Insulin Analog - Diabetes Mellitus, Type 1 | Phase 4 | Completed | Mannkind Corporation | 141 | 2023-07-07 | 2024-08-09 |
| Co-administration of Pramlintide and Insulin Via an Automated Dual-hormone Artificial Pancreas System in Adults With Type 1 Diabetes Rapid-Acting Insulin, Placebo, Pramlintide Acetate - Diabetes Mellitus, Type 1, Type 1 Diabetes | Not applicable | Unknown | McGill University | 26 | 2021-11-12 | 2023-03-15 |
| Intravenous Bolus-infusion Versus Sliding Scale of Insulin for Intra-operative Glycemic Control Rapid-Acting Insulin - Intraoperative Complications | Early Phase 1 | Completed | Ain Shams University | 60 | 2021-11-01 | 2022-10-25 |
| Afrezza® INHALE-1 Study in Pediatrics Afrezza, Rapid-acting Insulin Analog, Basal Insulin - Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2 | Phase 3 | Completed | Mannkind Corporation | 319 | 2021-09-29 | 2025-05-06 |
| A Study of Rapid-Acting Mealtime Insulin in Children and Adolescents With Newly Diagnosed Type 1 Diabetes Mellitus Rapid-Acting Insulin, Long acting insulin - Diabetes Mellitus, Type 1 Diabetes | Phase 4 | Completed | Emory University | 24 | 2019-11-27 | 2021-09-30 |
| Acarbose and Prandial Insulin for the Treatment of Gestational Diabetes Mellitus. Acarbose, Prandial insulin - Gestational Diabetes Mellitus in Pregnancy | Phase 3 | Terminated | Assistance Publique - Hôpitaux de Paris | 341 | 2018-07-04 | 2024-07-03 |
| The Efficacy of MDI Treatment With an Optimization Algorithm Adjusting Basal-Bolus Parameters in Children and Adolescents With Type 1 Diabetes at a Diabetes Camp Multiple Daily Injections: Slow acting insulin and Rapid acting insulin - Diabete Mellitus, Diabetes Mellitus, Type 1 | Not applicable | Completed | McGill University | 21 | 2018-07-02 | 2019-08-15 |
| Insulin in Treatment of Diabetes Mellitus With Pregnancy Basal insulin analogue, rapid acting insulin, Neutral Protamine Hagedorn - Diabetes | Not applicable | Completed | Assiut University | 110 | 2015-01-01 | 2021-01-27 |
| Evaluate the Efficacy and Safety of Saxagliptin Added to Insulin Monotherapy or to Insulin Combined With Metformin in Chinese Subjects With Type 2 Diabetes Who Have Inadequate Glycaemic Control Saxagliptin 5mg, Placebo for Saxagliptin - Type 2 Diabetes Mellitus | Phase 3 | Completed | AstraZeneca | 953 | 2014-05-07 | 2017-10-02 |
| A Study of Continuous Subcutaneous Insulin Infusion (CSII) Pump Function in Subjects With Type 1 Diabetes With Recombinant Human Hyaluronidase (rHuPH20) Rapid Acting insulin with pre-treatment of rHuPH20, Sham injection - Type 1 Diabetes Mellitus | Phase 4 | Completed | Halozyme Therapeutics | 14 | 2013-10-03 | 2019-02-01 |
| A Study to Characterize Regimens of Basal Insulin Intensified With Either Symlin® or Rapid Acting Insulin in Patients With Type 2 Diabetes pramlintide acetate (Symlin), rapid acting insulin (Humalog® [insulin lispro], Novolog® [insulin aspart], or Apidra® [insulin glulisine]), basal insulin (Lantus® [insulin glargine], or Levemir® [insulin detemir]) - Type 2 Diabetes Mellitus | Phase 4 | Completed | AstraZeneca | 112 | 2007-05-01 | 2015-04-14 |
| Early Diagnosis of Diabetes Mellitus in Patients With Cystic Fibrosis Repaglinide, short-acting Insulin (Actrapid) - Cystic Fibrosis, Diabetes Mellitus | Phase 3 | Completed | Mukoviszidose Institut gGmbH | 73 | 2001-09-01 | 2012-07-10 |
Diabetes Mellitus (9) · Insulin Resistance (7) · Diabetes Mellitus, Type 1 (6) · Diabetes Mellitus, Type 2 (3) · Respiratory Aspiration (2) · Corneal Ulcer (1) · Cystic Fibrosis (1) · Hyperglycemia (1) · Intraoperative Complications (1)
AstraZeneca (2) · Mannkind Corporation (2) · McGill University (2) · Ain Shams University (1) · Assistance Publique - Hôpitaux de Paris (1) · Assiut University (1) · Beijing Anzhen Hospital (1) · Benha University (1) · Emory University (1) · Halozyme Therapeutics (1) · Mukoviszidose Institut gGmbH (1)
United States (5) · Canada (2) · Egypt (2) · France (2) · Austria (1) · China (1) · Germany (1) · Italy (1)
Eric I Felner, MD (1) · Irl B. Hirsch, MD (1) · Kevin Kaiserman (1) · Kevin Kaiserman, MD (1) · Linong Ji, Professor (1) · Lisa Porter, MD (1) · Manfred Ballmann, Prof. Dr. (1) · Reinhard Holl, Prof. (1)
PMID 1244564, PMID 17337495, PMID 17387446, PMID 20092585, PMID 20199136, PMID 21871686, PMID 22081481, PMID 23809507, PMID 24620855, PMID 29144061, PMID 29199116, PMID 30025986, PMID 33075159, PMID 34483270, PMID 36617389